BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35660355)

  • 1. Extended Delay to Treatment for Stage III-IV Non-Small-Cell Lung Cancer and Survival: Balancing Risks During the COVID-19 Pandemic.
    Mayne NR; Bajaj SS; Powell J; Elser HC; Civiello BS; Fintelmann FJ; Li X; Yang CJ
    Clin Lung Cancer; 2022 Sep; 23(6):e362-e376. PubMed ID: 35660355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival.
    Mayne NR; Elser HC; Darling AJ; Raman V; Liou DZ; Colson YL; D'Amico TA; Yang CJ
    Ann Surg; 2021 May; 273(5):850-857. PubMed ID: 33630435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Extended Delayed Surgery for Indolent Lung Cancer or Part-Solid Ground Glass Nodules.
    Mayne NR; Elser H; Lin BK; Raman V; Liou D; Li X; D'Amico TA; Jeffrey Yang CF
    Ann Thorac Surg; 2022 Jun; 113(6):1827-1834. PubMed ID: 34329603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
    Bonomi P; Gale M; Rowland K; Taylor SG; Purl S; Reddy S; Lee MS; Phillips A; Kittle CF; Warren W
    Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):247-52. PubMed ID: 1846847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.
    Davidoff AJ; Gardner JF; Seal B; Edelman MJ
    J Thorac Oncol; 2011 May; 6(5):934-41. PubMed ID: 21372743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
    Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
    Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years.
    van der Drift MA; Karim-Kos HE; Siesling S; Groen HJ; Wouters MW; Coebergh JW; de Vries E; Janssen-Heijnen ML
    J Thorac Oncol; 2012 Feb; 7(2):291-8. PubMed ID: 22157366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
    Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
    Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
    Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
    Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung cancer in Spanish women: The WORLD07 project.
    Garrido P; Viñolas N; Isla D; Provencio M; Majem M; Artal A; Carcereny E; Garcia Campelo R; Lianes P; De La Peñas R; Felip E
    Eur J Cancer Care (Engl); 2019 Jan; 28(1):e12941. PubMed ID: 30277293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of timeliness of care on survival in non-small cell lung cancer patients.
    Radzikowska E; Roszkowski-Śliż K; Głaz P
    Pneumonol Alergol Pol; 2012; 80(5):422-9. PubMed ID: 22926903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A propensity score matching analysis of survival following segmentectomy or wedge resection in early-stage lung invasive adenocarcinoma or squamous cell carcinoma.
    Zhang Y; Sun Y; Chen H
    Oncotarget; 2016 Mar; 7(12):13880-5. PubMed ID: 26871600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
    Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.